Trial · NCT04856085
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants with treatment-emergent adverse events (TEAEs) | Up to 72 weeks | |
| Primary | Proportion of participants with serious adverse events (SAEs) | Up to 72 weeks | |
| Primary | Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment | Up to 48 weeks | |
| Primary | Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment | Up to 72 weeks | |
| Secondary | Absolute serum HBsAg and change from baseline across all timepoints in the study | Up to 110 weeks | |
| Secondary | Nadir and maximum reduction of serum HBsAg from baseline | Up to 110 weeks | |
| Secondary | Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification (LLOQ) for >= 24 weeks after discontinuation of all treatment, including NRTIs) | Up to 110 weeks | |
| Secondary | For hepatitis B e-antigen (HBeAg)-positive participants: Proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint | Up to 110 weeks | |
| Secondary | For HBeAg-positive participants: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion | Up to 110 weeks | |
| Secondary | Cmax | Up to 110 weeks | |
| Secondary | AUClast | Up to 110 weeks | |
| Secondary | t1/2 | Up to 110 weeks | |
| Secondary | CL/F | Up to 110 weeks | |
| Secondary | Number of participants with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434 | Up to 110 weeks | |
| Secondary | Proportion of participants meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation | Up to 60 weeks | |
| Secondary | Proportion of participants meeting criteria for NRTI retreatment | Up to 110 weeks | |
| Secondary | Proportion of participants achieving undetectable HBsAg and sustained suppression of HBV DNA [below the LLOQ, target not detected (TND)] >/= 24 weeks after discontinuation of all treatment, including NRTIs | Up to 110 weeks | |
| Secondary | Proportion of participants with serum HBsAg < 10 IU/mL at end of treatment | Up to 48 weeks | |
| Secondary | Proportion of participants with serum HBsAg < 10 IU/mL at 24 weeks post-end of treatment | Up to 72 weeks | 48 weeks treatment + 24 weeks post-end of treatment |
| Secondary | Proportion of participants with anti-HBs seroconversion | Up to 110 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04856085/registered